EFFICACY AND SAFETY IN THE USE OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS AT HIGH RISK OF FRACTURE IN AN OUTPATIENT CASE SERIES FROM THE MARCHE REGION

被引：0
|
作者：
Farina, A. [1 ]
Pingiotti, E. [1 ]
Martino, G. P. [1 ]
Bitti, G. [1 ]
Angelici, S. [1 ]
机构：
[1] Osped Civile A Murri, Internal Med, Fermo, Italy
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2024年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P147
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    E. Söreskog
    I. Lindberg
    J.A. Kanis
    K.E. Åkesson
    D. Willems
    M. Lorentzon
    O. Ström
    P. Berling
    F. Borgström
    Osteoporosis International, 2021, 32 : 585 - 594
  • [2] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    Soreskog, E.
    Lindberg, I.
    Kanis, J. A.
    Akesson, K. E.
    Willems, D.
    Lorentzon, M.
    Strom, O.
    Berling, P.
    Borgstrom, F.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 585 - 594
  • [3] Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture
    Turk, James R.
    Deaton, Aimee M.
    Yin, Jun
    Stolina, Marina
    Felx, Melanie
    Boyd, Gabrielle
    Bienvenu, Jean-Guy
    Varela, Aurore
    Guillot, Martin
    Holdsworth, Gill
    Wolfreys, Alison
    Dwyer, Denise
    Kumar, Sheetal, V
    de Koning, Emily M.
    Qu, Yusheng
    Engwall, Michael
    Locher, Kathrin
    Ward, Lucas D.
    Glaus, Charles
    He, Yudong D.
    Boyce, Rogely Waite
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2020, 115
  • [4] Romosozumab for the treatment of postmenopausal women at high risk of fracture
    Geusens, Piet
    Appelman-Dijkstra, Natasha
    Lems, Willem
    van den Bergh, Joop
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (01) : 11 - 19
  • [5] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
    Gielen, Evelien
    Aldven, Martina
    Kanis, John A.
    Borgstrom, Fredrik
    Senior, Emmanuelle
    Willems, Damon
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (07) : 1173 - 1183
  • [6] Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
    Lim, Sian Yik
    WOMENS HEALTH, 2022, 18
  • [7] Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
    Lim, Sian Yik
    WOMENS HEALTH, 2022, 18
  • [8] Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico
    Martinez, Juan Pablo Diaz
    de Maraumont, Therese Aubry
    Sanchez, Elly Natty
    Cordero, Luis Miguel Camacho
    Yeh, Eric
    PLOS ONE, 2025, 20 (02):
  • [9] Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk
    McClung, Michael R.
    Betah, Donald
    Deignan, Cynthia
    Shi, Yifei
    Timoshanko, Jen
    Cosman, Felicia
    ENDOCRINE PRACTICE, 2023, 29 (09) : 716 - 722
  • [10] Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
    Cosman, F.
    Crittenden, D. B.
    Adachi, J. D.
    Binkley, N.
    Czerwinski, E.
    Ferrari, S.
    Hofbauer, L. C.
    Lau, E.
    Lewiecki, E. M.
    Miyauchi, A.
    Zerbini, C. A. F.
    Milmont, C. E.
    Chen, L.
    Maddox, J.
    Meisner, P. D.
    Libanati, C.
    Grauer, A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345